Acute Illnesses and Injuries Related to Total Release Foggers — 10 States, 2007–2015
Weekly / February 2, 2018 / 67(4);125–130
Views: Views equals page views plus PDF downloadsMetric Details
Ruiling Liu, Ph.D1; Walter A. Alarcon, MD1; Geoffrey M. Calvert, MD1; Kathleen G. Aubin, MSPH2; John Beckman3,4; Karen R. Cummings, MPH5; Lucia S. Graham, PhD6; Sheila A. Higgins, MPH7; Prakash Mulay, MBBS8; Ketki Patel, PhD, MD9; Joanne B. Prado, MPH10; Abby Schwartz, MPH11; Derry Stover, MPH12; Justin Waltz, MPH13 (View author affiliations)View suggested citation and related materials
What is already known about this topic?
Total release foggers (TRFs) pose a risk for acute illness. As a result, the Environmental Protection Agency required manufacturers to place improved labels on all TRFs manufactured after September 2012.
What is added by this report?
During 2007–2015, a total of 3,222 acute TRF-related cases were identified from 10 states participating in the Sentinel Event Notification System for Occupational Risk (SENSOR)–Pesticides program, the California Department of Pesticide Regulation program, and poison control centers in Florida, Texas, and Washington. No statistically significant reduction in overall incidence of TRF-associated injuries and illnesses was observed in the first 3 years after the label revisions took effect. Failure to vacate treated premises during application and early reentry of treated premises were the two most commonly reported causes of TRF-related illness. Failure to vacate the premises and excessive fogger use were associated with moderate or high severity illness.
What are the implications for public health practice?
More comprehensive strategies are needed to reduce acute TRF-related illnesses, including promoting integrated pest management and identifying better approaches for motivating users to read and follow label instructions. Redesigning TRFs to prevent sudden, unexpected activation might also be useful.
Total release foggers (TRFs) (also known as “bug bombs”) are pesticide products often used indoors to kill insects. After an earlier report found that TRFs pose a risk for acute illness (1), the Environmental Protection Agency required improved labels on TRFs manufactured after September 2012 (2). To examine the early impact of relabeling, the magnitude and characteristics of acute TRF-related illness were evaluated for the period 2007–2015. A total of 3,222 TRF-related illnesses were identified in 10 participating states, based on three data sources: Sentinel Event Notification System for Occupational Risk–Pesticides (SENSOR) programs, the California Department of Pesticide Regulation (CDPR) program, and poison control centers (PCCs) in Florida, Texas, and Washington. No statistically significant decline in the overall TRF-illness incidence rate was found. Failure to vacate treated premises during application was the most commonly reported cause of exposure. To reduce TRF-related illness, integrated pest management strategies (3) need to be adopted, as well as better communication about the hazards and proper uses of TRFs. Redesigning TRFs to prevent sudden, unexpected activation might also be useful.
Acute TRF-related illnesses were identified from the SENSOR programs in 10 participating states (2007–2015),* CDPR† (2007–2014), and PCCs in Florida, Texas, and Washington (2007–2015). Complete PCC data were unavailable from the other seven states with SENSOR programs. Cases meeting all of the following criteria were included: exposure to TRFs with known active ingredients, at least two signs or symptoms related to or possibly related to TRF exposure, and no involvement of suicide or intentional harm to others. A total of 3,222 unique cases were identified.§ Cases were categorized as definite, probable, or possible based on case-level evidence.¶ The magnitude, trends, and characteristics of acute TRF-related illnesses were assessed. Incidence rates were calculated using U.S. Census standard population estimates as denominators (4). Poisson regression analyses were conducted to estimate incidence rate ratios (IRR) during 2013 (the first full year after label improvement when many TRF products on store shelves likely still had the old labels) and 2014–2015 (the period after label improvement when most TRF products likely had new labels) compared with 2007–2012 (the period before label improvements) for all cases and by reported causes of exposure, controlling for state to adjust for discordance in missing data across states. Stepwise logistic regression analysis was conducted to explore reported causes associated with more severe illness** (high or moderate versus low severity), adjusting for age, sex, and preexisting health conditions.
Overall, 3,573 cases were identified, including 1,843 from the SENSOR and CDPR programs and 1,730 from PCCs in Florida, Texas, and Washington (Table 1); 351 cases were identified from both the SENSOR programs and PCCs in Florida, Texas, or Washington, resulting in a total of 3,222 unique cases. Among cases from the SENSOR and CDPR programs, 87% were reported to the programs by PCCs; 6% were classified as definite, 20% as probable, and 74% as possible. After combining unique cases from the three data sources, the overall incidence rates in the 10 states during 2007–2012, 2013, and 2014–2015 were 27.0, 26.3, and 29.5 per 10 million population, respectively. The adjusted incidence rate did not change in 2013 or 2014–2015, compared with 2007–2012 (Table 2).
Five percent of cases occurred in children aged 0–5 years and 14% in adults aged ≥60 years (Table 1); the median age was 40 years. Approximately 56% occurred in females; 92% of exposures happened in private residences, and 91% were not work-related. Respiratory signs and symptoms (cough, upper respiratory pain or irritation, and dyspnea) and gastrointestinal signs and symptoms (vomiting, nausea, and abdominal pain or cramping) were the most commonly reported. Severity was classified as low, moderate, and high for 78%, 21%, and 0.7% of the illnesses, respectively. Four (0.1%) cases were fatal. Approximately 93% of cases involved exposure to the TRF active ingredients pyrethroid (78%) or pyrethrin (24%). The most commonly reported causes of exposure were failure to vacate treated premises during application, early reentry into treated premises, inability to vacate treated premises before TRF discharge, and inadequate ventilation of treated premises; approximately 4% of cases were caused by TRF discharge by children aged <13 years (Table 1). Incidence rates associated with failure to vacate premises during application increased during 2014–2015 compared with 2007–2012 (adjusted IRR = 1.39, p = 0.002), whereas rates related to excessive fogger use (i.e., using more foggers than necessary) decreased (adjusted IRR = 0.43, p = 0.001) (Table 2). Moderate or high severity illness were more common among males, persons aged >60 years, those with preexisting asthma, and those who failed to vacate premises during application, or who were exposed to excessive TRFs (Table 3).
A previous study identified 466 acute TRF-related illnesses in eight states during 2001–2006 (1) for a crude average annual incidence rate of seven cases per 10 million population. This study identified 3,222 cases in 10 states during 2007–2015, with an average annual incidence rate of 27 per 10 million population. This increase likely resulted from including all PCC cases from Florida, Texas, and Washington and conducting a more comprehensive search for TRF-related cases in the SENSOR database. The increase might also partly result from increased TRF use and improved case ascertainment in recent years.
The Environmental Protection Agency required registrants of all TRFs manufactured after September 2012 to adopt improved labels that use pictures to illustrate some instructions and precautions and emphasize actions such as vacating treated premises for at least 2 hours, ventilating treated areas before reentry for an additional 2 hours or until no odor is detected, and not using more foggers than necessary. However, exposure narratives from case reports suggested that many users did not follow or read label instructions. Although many users left the treated area or room, they did not leave the treated premises as specified by the label. Early reentry usually involved entering treated premises shortly after application, often to turn off smoke alarms or retrieve pets or forgotten items. Some users were exposed when they entered premises to initiate ventilation. TRF labels do not provide guidance on how to minimize exposure when initiating ventilation. Some users ventilated treated premises for the recommended length of time or longer, but still became ill, suggesting that ventilation might be inadequate or the recommended period might be insufficient to fully eliminate TRF residuals before occupancy. Some were sprayed in the face or at close range because of nozzle malfunction or inappropriate TRF activation (e.g., pointing the nozzle in the wrong direction), suggesting a need for better nozzle designs and a label picture showing how to appropriately set off a TRF.
The reason that the overall illness incidence rate did not decline during 2014–2015 is unknown. Some TRFs used during 2014–2015 might have had old labels, or more time might be needed for the protective effects of the revised labels to be realized. Many users might not have read or followed label instructions. However, incidence rates associated with excessive fogger use did decline, suggesting that simplified label statements and pictures addressing this risk factor might have been effective.
Early reentry likely led to brief exposure to TRF and more commonly caused low severity illnesses, whereas failure to vacate treated premises or excessive fogger use likely resulted in longer or higher concentration exposures and more commonly caused moderate or high severity illnesses. Preexisting asthma was associated with moderate or high severity illnesses, indicating that a warning message for persons with asthma might be necessary on the labels. Although a previous Environmental Protection Agency assessment reported no association between pyrethrin or pyrethroid exposure and asthma (5), a recent study found that among persons with acute pesticide-related illness, those with pyrethrin or pyrethroid exposures were significantly more likely to have asthmatic symptoms than were those with other pesticide exposures (6).
The findings in this report are subject to at least five limitations. First, because reporting to the surveillance systems and PCCs is passive, and because many persons with low severity cases do not seek medical care, acute TRF-related cases were likely underreported. Second, some cases might be false positives because many of the reported symptoms are not specific to TRF exposure and might have been caused by unrelated factors or conditions. Third, because the number of TRF users or another proxy for TRF users were not available, the overall population in the 10 states was used as the denominator to estimate incidence rates. Trends in incidence rates might be different if the correlation between TRF users and the overall population size was not consistent over time; incidence rates after the label revision would be overestimated if TRF users increased more sharply than the overall population during 2013–2015. Fourth, data were available from only 10 states and might not be representative of the entire United States. Finally, data were available for only 3 years after the new label requirements took effect, and data were missing from four of the 10 states in 2014 or 2015. However, results and conclusions were essentially unchanged when sensitivity analyses were performed that used data from different groups of states (e.g., excluding states with missing data from analysis) and used different post-label periods (e.g., 2014 only and 2015 only). Nonetheless, the evaluation of the early impact from the Environmental Protection Agency’s intervention to reduce TRF-related illnesses should be considered preliminary and interpreted with caution.
Additional efforts are needed to prevent acute TRF-related illnesses, including promoting integrated pest management (3) to prevent and mitigate pest infestations and identifying more effective strategies to educate users about reading and following label instructions. Redesigning TRFs to prevent sudden, unexpected activation might also be useful.
Staff members from the SENSOR program, poison control centers from SENSOR participating states, and the California Department of Pesticide Regulation; the Washington Poison Center; Mathias Forrester, Texas Department of State Health Services; Jay Schauben, Florida Poison Information Center.
Conflict of Interest
No conflicts of interest were reported.
Corresponding author: Walter A. Alarcon, email@example.com.
1National Institute for Occupational Safety and Health, CDC; 2Louisiana Department of Health; 3California Department of Public Health; 4Public Health Institute, Oakland, California; 5New York State Department of Health; 6California Department of Pesticide Registration; 7North Carolina Division of Public Health; 8Florida Department of Health; 9Texas Department of State Health Services; 10Washington State Department of Health; 11Michigan Department of Health and Human Services; 12Nebraska Department of Health and Human Services; 13Oregon Health Authority.
* Under the SENSOR-Pesticides program, CDC provides cooperative agreement funding and technical support to state health departments to conduct surveillance for acute, occupational, pesticide-related illness and injury. Funding support is also provided by the Environmental Protection Agency. In 2017, a total of 13 states participated in this program. Data were available for this study for the period 2007–2013 in Oregon; 2007–2014 in California, Nebraska, and New York; and 2007–2015 in Florida, Louisiana, Michigan, North Carolina, Texas, and Washington. https://www.cdc.gov/niosh/topics/pesticides/overview.html.
† In California, two programs identify cases of acute pesticide-related illness and injury; one is located at the California Department for Public Health (CDPH) and participates in the SENSOR program; the other is the Pesticide Illness Surveillance Program (PISP), administered by CDPR. PISP operates similarly to the SENSOR program, but the case definition and the variables used to characterize cases differ between the two programs (http://www.cdpr.ca.gov/docs/whs/pisp.htm). Although PISP does not formally participate in the SENSOR program, both programs collaborate on joint activities. CDPH collects only work-related cases of acute pesticide-related illness and injury; PISP collects data for work-related and nonwork-related acute pesticide-related illness and injury. To ensure California cases were counted only once, CDPH cross-referenced its cases with those from PISP using name, date of illness and injury and, if available, Social Security number and date of birth.
§ 7,441 persons with TRF exposure were identified, and 3,222 unique cases remained after exclusions. The following persons were excluded: fewer than two signs or symptoms reported (3,638), suicide or intentional harm to others (24), and exposed to TRF products with unknown active ingredients (193). Also, 13 cases were reported by both the California SENSOR program and CDPR, and 351 by both SENSOR programs and PCCs in Florida, Texas, or Washington.
¶ In the SENSOR program, cases are defined as definite (objective evidence is available to confirm exposure and health effects), probable (a combination of objective and self-reported data), and possible (self-reported exposure and health effects data) (https://www.cdc.gov/niosh/topics/pesticides/pdfs/casedef.pdf). Cases from CDPR are categorized as definite (both physical and medical evidence documenting exposure and consequent health effects), probable (limited and circumstantial evidence supporting a relationship to pesticide exposure) and possible (health effects correspond generally to the reported exposure, but evidence is not available to support a relationship). http://apps.cdpr.ca.gov/calpiq/. Case categorization was not available for cases obtained only from PCCs in Florida, Texas, and Washington.
** Illness and injury severity for SENSOR and CDPR cases was categorized into four groups using the following standardized criteria: low severity (the condition usually resolves without treatment and <3 days are lost from work); moderate severity (the condition is not life-threatening but requires medical treatment; no residual impairment is expected, and time lost from work is ≤5 days); high severity (the condition is life threatening, requires hospitalization, often has >5 days lost from work, and might result in permanent impairment); and fatal (https://www.cdc.gov/niosh/topics/pesticides/statebase.html). For cases from PCCs in Florida, Texas, and Washington, case severity was based on the medical outcomes reported. Those cases reported with “death,” “major effect,” “moderate effect” and “minor effect” were classified as death, high severity, moderate severity, and low severity, respectively. PCC cases reported with “not followed, minimal clinical effects possible (no more than minor effect possible)” or “unable to follow, judged as a potentially toxic exposure” were also classified as low severity, unless, for those with “unable to follow, judged as a potentially toxic exposure,” if the call to the PCC arose from a health care facility and the case had at least two moderate or high severity signs or symptoms (https://www.cdc.gov/niosh/topics/pesticides/pdfs/pest-sitablev6.pdf), then the case was classified as moderate severity.
- CDC. Illnesses and injuries related to total release foggers—eight states, 2001–2006. MMWR Morb Mortal Wkly Rep 2008;57:1125–9. PubMed
- Environmental Protection Agency. Update: total release foggers [Archive]. Washington, DC: Environmental Protection Agency. https://archive.epa.gov/pesticides/ppdc/web/pdf/session6-trf.pdf
- Blessing A, ed. Pesticides and pest prevention strategies for the home, lawn, and garden. West Lafayette, IN: Purdue University of Cooperative Extension Service; 2001. https://www.cdc.gov/niosh/topics/pesticides/pdfs/casedef.pdf
- US Census Bureau. Population estimates. Washington, DC: US Census Bureau; 2016. https://www2.census.gov/programs-surveys/popest/tables
- Environmental Protection Agency. A review of the relationship between pyrethrins, pyrethroid exposure and asthma and allergies. Washington, DC: Environmental Protection Agency; 2009. https://www.epa.gov/sites/production/files/2015-08/documents/pyrethrins-pyrethroids-asthma-allergy-9-18-09.pdf
- Hudson NL, Kasner EJ, Beckman J, et al. Characteristics and magnitude of acute pesticide-related illnesses and injuries associated with pyrethrin and pyrethroid exposures—11 states, 2000–2008. Am J Ind Med 2014;57:15–30. CrossRef PubMed
Suggested citation for this article: Liu R, Alarcon WA, Calvert GM, et al. Acute Illnesses and Injuries Related to Total Release Foggers — 10 States, 2007–2015. MMWR Morb Mortal Wkly Rep 2018;67:125–130. DOI: http://dx.doi.org/10.15585/mmwr.mm6704a4.
Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of
Health and Human Services.
References to non-CDC sites on the Internet are provided as a service to MMWR readers and do not constitute or imply endorsement of these organizations or their programs by CDC or the U.S. Department of Health and Human Services. CDC is not responsible for the content of pages found at these sites. URL addresses listed in MMWR were current as of the date of publication.
All HTML versions of MMWR articles are generated from final proofs through an automated process. This conversion might result in character translation or format errors in the HTML version. Users are referred to the electronic PDF version (https://www.cdc.gov/mmwr) and/or the original MMWR paper copy for printable versions of official text, figures, and tables.
Questions or messages regarding errors in formatting should be addressed to firstname.lastname@example.org.
- Page last reviewed: February 1, 2018
- Page last updated: February 1, 2018
- Content source: